Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells

Medical Oncology

Volumn 28, Issue 1, 2011, Pages 270-278

  El Kholy, Noura M ^a   Sallam, Maha M ^a   Ahmed, Manal B ^a   Sallam, Reem M ^a   Asfour, Inas A ^b   Hammouda, Jehad A ^a   Habib, Haidy Z ^a   Abu Zahra, Fatima ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

1 methyl tryptophan; 3 dioxygenase; Acute myeloid leukemia; Indoleamine 2

Indexed keywords

1 METHYL TRYPTOPHAN; DOXORUBICIN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLAST CELL; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 85027917817     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-010-9459-6     Document Type: Article

References (29)

1. X Liu RC Newton SM Friedman PA Scherle 2009 Indoleamine 2, 3-dioxygenase, an emerging target for anti-cancer therapy Curr Cancer Drug Targets 9 938 952 20025603 10.2174/156800909790192374 1:CAS:528:DC%2BC3cXhslKnsLk%3D
2. C Uyttenhove, et al. 2003 Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase Nat Med 9 1269 1274 14502282 10.1038/nm934 1:CAS:528:DC%2BD3sXns1Clu7c%3D (Pubitemid 37279849)
3. A Curti, et al. 2007 Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells Blood 109 7 2871 2877 17164341 1:CAS:528:DC%2BD2sXjvVyns7c%3D (Pubitemid 46482083)
4. S Corm, et al. 2009 Indoleamine 2, 3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma Leuk Res 33 3 490 494 18639339 10.1016/j.leukres.2008.06. 014 1:CAS:528:DC%2BD1MXhtVCqsrY%3D
5. AL Mellor, et al. 2003 Tryptophan catabolism and T cell responses Adv Exp Med Biol 527 27 35 15206713 1:CAS:528:DC%2BD2cXktlOjs7o%3D (Pubitemid 38197625)
6. G Frumento, et al. 2002 Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase J Exp Med 196 459 468 12186838 10.1084/jem.20020121 1:CAS:528:DC%2BD38XmsV2htLk%3D
7. MD Chiesa, et al. 2006 The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function Blood 108 4118 4125 16902152 10.1182/blood-2006-03-006700 (Pubitemid 44913283)
8. J Wang 2006 Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35 J Biol Chem 281 22021 22028 16754668 10.1074/jbc.M603503200 1:CAS:528:DC%2BD28XnsVOmsbo%3D (Pubitemid 44181906)
9. K Ino, et al. 2006 Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer Br J Cancer 95 1555 1561 17117179 10.1038/sj.bjc.6603477 1:CAS:528:DC%2BD28Xht1Cntr3F (Pubitemid 44863359)
10. G Brandacher, et al. 2006 Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: impact on tumor-infiltrating cells Clin Cancer Res 12 1144 1151 16489067 10.1158/1078-0432.CCR-05-1966 1:CAS:528:DC%2BD28XhsFalt7g%3D (Pubitemid 43342502)
11. DH Munn AL Mellor 2006 The tumor-draining lymph node as an immune privileged site Immunol Rev 213 146 158 16972902 10.1111/j.1600-065X.2006.00444. x (Pubitemid 44401499)
12. SB Mckenzie 2005 Advances in understanding the biology and genetics of acute myeloid leukemia Clin Lab Sci 18 28 37 15747784
13. XQ Tang, et al. 2006 Indoleamine 2, 3- dioxygenase activity in acute myeloid leukemia cells contributing to tumor immune escape J Exp Hematol/Chin Assoc Pathophysiol 14 3 539 542 1:CAS:528:DC%2BD2sXht1WqsrvP
14. A Curti, et al. 2007 Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2, 3-dioxygenase Leukemia. 21 353 355 17170728 10.1038/sj.leu.2404485 1:CAS:528:DC%2BD2sXotFGqsA%3D%3D (Pubitemid 46158132)
15. MED Chamuleau, et al. 2008 High INDO (indoleamine 2, 3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome Haematologica 93 1894 1898 19050070 10.3324/haematol.13112 1:CAS:528:DC%2BD1MXhtFyntbk%3D
16. C Nilsson, et al. 2008 Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy swedish and tanzanian subjects Clin Vaccine Immunol 15 4 585 589 18287577 10.1128/CVI.00161-07 1:CAS:528:DC%2BD1cXlvFejs7Y%3D (Pubitemid 351967037)
17. W Daubener, et al. 1994 A new simple bioassay for human IFN-gamma J Immunol Methods 168 39 47 8288893 10.1016/0022-1759(94)90207-0 1:STN:280:DyaK2c7hslymsQ%3D%3D (Pubitemid 24035863)
18. MA Bradford 1976 A rapid and sensitive method for the quantition of microgram quantities of protein utilizing the principle of protein dye binding Anal Biochem 72 248 254 942051 10.1016/0003-2697(76)90527-3 1:CAS:528: DyaE28XksVehtrY%3D
19. Y Kudo CA Boyd 2001 The role of l-tryptophan transport in l-tryptophan degradation by indoleamine 2, 3-dioxygenase in human placental explants J Physiol 531 2 417 423 11230514 10.1111/j.1469-7793.2001.0417i.x 1:CAS:528:DC%2BD3MXisFWgtL8%3D (Pubitemid 32229667)
20. A Curti S Trabanelli V Salvestrini M Baccarani RM Lemoli 2009 The role of indoleamine 2, 3-dioxygenase in the induction of immune tolerance: focus on hematology Blood 113 11 2394 2401 19023117 10.1182/blood-2008-07-144485 1:CAS:528:DC%2BD1MXjsFKhurg%3D
21. S Broomfield, et al. 2005 Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy Cancer Res 65 7580 7584 16140921 1:CAS:528: DC%2BD2MXpslaitLo%3D (Pubitemid 41297228)
22. W Dummer, et al. 2002 T cell homeostatic proliferation elicits effective antitumor autoimmunity J Clin Invest 110 185 192 12122110 1:CAS:528: DC%2BD38XlsVGlsb8%3D (Pubitemid 34787355)
23. C King A Ilic K Koelsch N Sarvetnick 2004 Homeostatic expansion of T cells during immune insufficiency generates autoimmunity Cell 117 265 277 15084263 10.1016/S0092-8674(04)00335-6 1:CAS:528:DC%2BD2cXjsFyru70%3D (Pubitemid 38496245)
24. IE Brown C Blank J Kline AK Kacha TF Gajewski 2006 Homeostatic proliferation as an isolated variable reverses CD8+ T Cell anergy and promotes tumor rejection J Immunol 177 4521 4529 16982889 1:CAS:528:DC%2BD28Xps1Gguro%3D (Pubitemid 44469783)
25. M Beyer, et al. 2005 Reduced frequencies and suppressive function of CD4+ CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine Blood 106 2018 2025 15914560 10.1182/blood-2005-02-0642 1:CAS:528:DC%2BD2MXhtVWksLrM (Pubitemid 41291715)
26. DH Munn, et al. 2004 Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes J Clin Invest 114 280 290 15254595 1:CAS:528:DC%2BD2cXlvFWmsbg%3D (Pubitemid 39071633)
27. AJ Muller JB DuHadaway PS Donover E Sutanto-Ward GC Prendergast 2005 Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy Nat Med 11 312 319 15711557 10.1038/nm1196 1:CAS:528:DC%2BD2MXhvVSru7c%3D (Pubitemid 40460560)
28. M Friberg, et al. 2002 Indoleamine 2, 3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection Int J Cancer 101 151 155 12209992 10.1002/ijc.10645 1:CAS:528:DC%2BD38XmslCksrw%3D (Pubitemid 34970907)
29. J Zeng, et al. 2009 Prevention of spontaneous tumor development in a ret transgenic Mouse model by ret peptide vaccination with indoleamine 2, 3-dioxygenase inhibitor 1-methyl tryptophan Cancer Res 69 9 3963 3970 19383920 10.1158/0008-5472.CAN-08-2476 1:CAS:528:DC%2BD1MXltFOksbs%3D